| Jeffrey John Sekula, MD | |
|
2 Ellinwood Court, New Hartford, NY 13413 | |
| (315) 724-1012 | |
| (315) 724-5219 |
| Full Name | Jeffrey John Sekula |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 28 Years |
| Location | 2 Ellinwood Court, New Hartford, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518946060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 165368 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rome Memorial Hospital, Inc | Rome, NY | Hospital |
| Faxton-st Luke's Healthcare | Utica, NY | Hospital |
| St Elizabeth Medical Center | Utica, NY | Hospital |
| Lewis County General Hospital | Lowville, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Medical Professionals Of Ny Pllc | 0749378123 | 62 |
News Archive
Beyond the tragic surges in hospitalizations and deaths, the first months of the COVID-19 pandemic disrupted healthcare for people with a wide range of medical conditions - including cancer.
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.
Scientists at the Johns Hopkins Kimmel Cancer Center and University of Melbourne report they have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease's return in some — but not all — of a small group of patients with early-stage colon cancer.
St. Jude Medical, Inc., a global medical device company, announced today it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine, and Switzerland's Lausanne University Hospital may have found it.
› Verified 4 days ago
| Entity Name | United Health Services Hospitals, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962463851 PECOS PAC ID: 5193610533 Enrollment ID: O20040216001017 |
News Archive
Beyond the tragic surges in hospitalizations and deaths, the first months of the COVID-19 pandemic disrupted healthcare for people with a wide range of medical conditions - including cancer.
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.
Scientists at the Johns Hopkins Kimmel Cancer Center and University of Melbourne report they have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease's return in some — but not all — of a small group of patients with early-stage colon cancer.
St. Jude Medical, Inc., a global medical device company, announced today it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine, and Switzerland's Lausanne University Hospital may have found it.
› Verified 4 days ago
| Entity Name | Associated Medical Professionals Of Ny Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467659060 PECOS PAC ID: 0749378123 Enrollment ID: O20071119000351 |
News Archive
Beyond the tragic surges in hospitalizations and deaths, the first months of the COVID-19 pandemic disrupted healthcare for people with a wide range of medical conditions - including cancer.
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.
Scientists at the Johns Hopkins Kimmel Cancer Center and University of Melbourne report they have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease's return in some — but not all — of a small group of patients with early-stage colon cancer.
St. Jude Medical, Inc., a global medical device company, announced today it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine, and Switzerland's Lausanne University Hospital may have found it.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey John Sekula, MD 1226 E Water St, Syracuse, NY 13210-1155 Ph: (315) 478-4185 | Jeffrey John Sekula, MD 2 Ellinwood Court, New Hartford, NY 13413 Ph: (315) 724-1012 |
News Archive
Beyond the tragic surges in hospitalizations and deaths, the first months of the COVID-19 pandemic disrupted healthcare for people with a wide range of medical conditions - including cancer.
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency.
Scientists at the Johns Hopkins Kimmel Cancer Center and University of Melbourne report they have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease's return in some — but not all — of a small group of patients with early-stage colon cancer.
St. Jude Medical, Inc., a global medical device company, announced today it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine, and Switzerland's Lausanne University Hospital may have found it.
› Verified 4 days ago
William A Mandour, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2 Ellinwood Dr, New Hartford, NY 13413 Phone: 315-724-1012 Fax: 315-724-5219 | |
Ronald I Kaye, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Ellinwood Dr, New Hartford, NY 13413 Phone: 315-724-1012 Fax: 315-724-5219 | |
Dr. Naeem Samad, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1729 Burrstone Rd, New Hartford, NY 13413 Phone: 315-798-1700 Fax: 315-798-1707 | |
Daniel Richard Welchons, Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Ellinwood Dr, Apt 19, New Hartford, NY 13413 Phone: 315-724-1012 | |
Robert P Fleischer, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Ellinwood Dr, New Hartford, NY 13413 Phone: 315-724-1012 Fax: 315-724-5219 | |
Jonathan D Block, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Ellinwood Dr, New Hartford, NY 13413 Phone: 315-724-1012 Fax: 315-724-5219 |